15583-16-1

Basic information

• Product Name: 3-(2-PYRIDINYL)PROPYLAMINE
• Synonyms: ASINEX-REAG BAS 10145168;3-PYRIDIN-2-YL-PROPYLAMINE;3-(2-PYRIDINYL)PROPYLAMINE;3-PYRIDIN-2-YLPROPAN-1-AMINE;OTAVA-BB 1038704;TIMTEC-BB SBB012768;(3-pyridin-2-ylpropyl)amine(SALTDATA: FREE);2-PyridinepropanaMine
• CAS NO: 15583-16-1
• Molecular Formula: C₈H₁₂N₂
• Molecular Weight: 136.19
• Mol File: 15583-16-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 227.5 °C at 760 mmHg
• Flash Point: 112 °C
• Appearance: /
• Density: 1.003 g/cm³
• Vapor Pressure: 0.0771mmHg at 25°C
• Refractive Index: 1.532
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.88±0.10(Predicted)
• CAS DataBase Reference: 3-(2-PYRIDINYL)PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-PYRIDINYL)PROPYLAMINE(15583-16-1)
• EPA Substance Registry System: 3-(2-PYRIDINYL)PROPYLAMINE(15583-16-1)

Safety Data

• Hazardous Substances Data: 15583-16-1(Hazardous Substances Data)

Usage

Uses

3-(pyridin-2-yl)propan-1-amine is used in the preparation of 2,4,6-s-triazine derivatives with biological and anti-malarial properties.

InChI:InChI=1/C8H12N2/c9-6-3-5-8-4-1-2-7-10-8/h1-2,4,7H,3,5-6,9H2

Upstream product

• 35549-47-4 2-(2-Cyanoethyl)pyridine 
• 100-69-6 2-vinylpyridine 
• 16927-00-7 2-(2-chloroethyl)pyridine 
• 2859-68-9 3-(pyridin-2-yl)-propanol 
• 838892-94-7 2-[3-(pyridin-2-yl)propyl]isoindoline-1,3-dione 

Downstream Products

• 1262317-07-6 4,5-dimethyl-N-(3-pyridin-2-ylpropyl)benzene-1,2-diamine 
• 1262317-06-5 4,5-dimethyl-2-nitro-N-(3-pyridin-2-ylpropyl)aniline 
• 1364408-61-6 N₁-(3,3-diphenylpropanoyl)-N₂-[3-(pyridin-2-yl)propyl]guanidine 
• 1555938-99-2 N₁-(3-phenylbutanoyl)-N₂-[3-(pyridin-2-yl)propyl]guanidine 

Relevant articles and documents

Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery

Using structure-guided design, several cell based assays, and microdosed positron emission tomography (PET) imaging, we identified a series of highly potent, selective, and brain-penetrant oxazole-4-carboxamide-based inhibitors of glycogen synthase kinase-3 (GSK-3). An isotopologue of our first-generation lead, [3H]PF-367, demonstrates selective and specific target engagement in vitro, irrespective of the activation state. We discovered substantial ubiquitous GSK-3-specific radioligand binding in Tg2576 Alzheimer's disease (AD), suggesting application for these compounds in AD diagnosis and identified [11C]OCM-44 as our lead GSK-3 radiotracer, with optimized brain uptake by PET imaging in nonhuman primates. GSK-3β-isozyme selectivity was assessed to reveal OCM-51, the most potent (IC50 = 0.030 nM) and selective (>10-fold GSK-3β/GSK-3α) GSK-3β inhibitor known to date. Inhibition of CRMP2T514 and tau phosphorylation, as well as favorable therapeutic window against WNT/β-catenin signaling activation, was observed in cells.

Synthesis, SAR and selectivity of 2-acyl- and 2-cyano-1-hetarylalkyl- guanidines at the four histamine receptor subtypes: A bioisosteric approach

In the search for potential bioisosteres of the 4-imidazolyl ring in acylguanidines (e.g. UR-AK24), known to possess affinity to several histamine receptor subtypes (HxR, x = 1-4), and cyanoguanidine-type H 4R agonists (e.g. UR-PI376

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun